证券代码：002932 证券简称：明德生物 公告编号：2026-007 武汉明德生物科技股份有限公司 关于增资并收购蓝怡（湖南）医疗器械有限公司股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 武汉明德生物科技股份有限公司（以下简称"公司"）于 2026 年 1 月 19 日召开第五届董事会第三次会议，审议并通过了《关于增资并收购蓝怡（湖南） 医疗器械有限公司股权的议案》。同意在蓝怡科技集团股份有限公司（以下简称 "蓝怡集团"）与蓝怡（湖南）医疗器械有限公司（以下简称"湖南蓝怡"）已 完成历史债权债务的抵扣、转化或转移相关协议签署的前提下，公司首期以现金 3,570.10万元，通过增资及股权收购方式取得蓝怡集团持有的湖南蓝怡51%股权； 同时蓝怡集团与嘉善禾欣咨询管理合伙企业（有限合伙）（以下简称"嘉善禾欣"） 达成协议，嘉善禾欣受让蓝怡集团持有的湖南蓝怡股权，对应湖南蓝怡首期收购 交割后的持股比例为 20%。首期收购后，湖南蓝怡将成为公司控股子公司，纳入 公司合并报表范围；在湖南蓝怡于 2026 年度至 2028 年度相关经营情况 ...

Group 1 - The core point of the news is that Mingde Biological experienced a slight decline in stock price, with a trading volume of 59.55 million yuan on February 2, and notable financing activities indicating a high level of market interest [1] - On February 2, Mingde Biological had a financing buy-in amount of 9.26 million yuan and a net financing buy of 0.53 million yuan, with a total financing and securities balance of 130 million yuan, which is 2.91% of its circulating market value [1] - The company’s main business includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, with a revenue composition of 65.04% from in vitro diagnostic products, 21.91% from third-party medical testing, and 13.05% from agency business and others [1] Group 2 - As of January 20, the number of shareholders of Mingde Biological decreased by 15.73% to 24,800, while the average circulating shares per person increased by 18.66% to 6,302 shares [2] - For the period from January to September 2025, Mingde Biological achieved an operating income of 227 million yuan, a year-on-year increase of 0.53%, but the net profit attributable to the parent company decreased by 83.30% to 13.52 million yuan [2] - The company has distributed a total of 1.76 billion yuan in dividends since its A-share listing, with 875 million yuan distributed in the last three years [2]

Core Viewpoint - Mingde Biological is planning two acquisitions within a month, including a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for 35.7 million yuan, despite Hunan Lanyi's negative net assets and consecutive losses [1][2]. Group 1: Acquisition Details - The acquisition of Hunan Lanyi aims to enhance synergy and core competitiveness, focusing on complementary industry chains to improve comprehensive service capabilities [1][2]. - Hunan Lanyi, established in September 2020, specializes in IVD instruments and reagents, recognized as a national high-tech enterprise and a "little giant" in specialized fields [2]. - The acquisition structure includes Mingde acquiring 51% of Hunan Lanyi, while related parties will hold an additional 20%, with plans for full control if performance targets are met [2][3]. Group 2: Financial Performance and Projections - Hunan Lanyi reported a net asset of -62.42 million yuan and consecutive losses of 20.68 million yuan in 2024 and 23.98 million yuan in the first three quarters of 2025 [1]. - Mingde Biological's projected net profit for 2025 is expected to decline by 75.85% to 83.9%, ranging from 12 million to 18 million yuan, primarily due to decreased investment income and increased credit impairment losses [5]. - The financial performance of Wuhan Bikaier, another target for acquisition, shows stable revenue and profit, with 2023 revenues of 168 million yuan and net profit of 12.64 million yuan [4].

Core Insights - Mingde Biological has initiated two equity acquisitions to focus on emergency rescue and in vitro diagnostic instruments, driven by declining COVID-19 testing business and increasing competition in the in vitro diagnostic industry [1][6] Group 1: Acquisition Details - On December 31, 2025, Mingde Biological signed a framework agreement with Blue Sail Medical to acquire 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. for cash [2] - Wuhan Bikaier, a leader in emergency rescue, reported a revenue of 165 million yuan and a net profit of 13.87 million yuan in 2024, with a revenue of 75.8 million yuan and a net profit of 7.52 million yuan in the first half of 2025 [2] - The acquisition aims to enhance Mingde Biological's market position in critical care by integrating emergency protection services into industrial and household scenarios [2] Group 2: Second Acquisition - On January 20, 2026, Mingde Biological announced a plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total price of 35.71 million yuan, making it a subsidiary [3][4] - Hunan Lanyi focuses on IVD instruments and has significant potential in the market, particularly in glycosylated hemoglobin testing [4] - The acquisition includes performance commitments, with Hunan Lanyi required to achieve an average net profit of at least 20 million yuan over three years to trigger further acquisition phases [5] Group 3: Financial Performance - Mingde Biological's revenue has faced significant declines, with 2023 and 2024 revenues at approximately 750 million yuan and 350 million yuan, representing year-on-year declines of 92.88% and 53.30% respectively [6] - The company reported a net profit of approximately 74.93 million yuan in 2023, down 9.22% year-on-year, and a net profit of about 74.52 million yuan in 2024, down 0.54% year-on-year [6] - As of September 30, 2025, the company's cash reserves were 184 million yuan, a decrease of 63% from the beginning of the period [6]

Core Viewpoint - Mingde Bio has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expectations of a net profit attributable to shareholders ranging from 12 million to 18 million yuan, representing a year-on-year decrease of 75.85% to 83.90% [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -98 million and -78 million yuan for 2025 [1] - The decline in net profit is primarily attributed to a substantial decrease in investment income and other income, along with an increase in credit impairment losses [1] Government Subsidies and Investment Income - During the reporting period, the amount of government subsidies received by the company decreased by over 40 million yuan compared to the same period last year [1] - Investment income has also seen a decline of over 30 million yuan year-on-year, influenced by the continuous decline in domestic financial market interest rates and lower yields on the company's financial products [1] Credit Impairment Losses - The company experienced a reduction in the collection of overdue accounts receivable compared to the previous year, leading to a decrease of over 30 million yuan in the reversal of impairment provisions for receivables that underwent individual impairment testing [1]

Financial Performance Expectations - The company expects a net profit of between 12 million to 18 million yuan for 2025, representing a decline of 75.85% to 83.90% compared to the previous year[4]. - The net profit attributable to shareholders is projected to decrease by over 50% year-on-year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between -98 million to -78 million yuan, an increase of 30.17% to 44.42% compared to the previous year[4]. - Basic earnings per share are expected to be between 0.05 to 0.08 yuan, down from 0.33 yuan in the previous year[4]. Revenue and Income Changes - Government subsidies received decreased by over 40 million yuan compared to the same period last year[3]. - Investment income is expected to decline by over 30 million yuan year-on-year due to lower yields from financial products[3]. - The company anticipates a credit impairment loss increase due to lower collection of overdue receivables and reduced reversal of impairment provisions[3]. Operational Strategy and Caution - The company will continue to optimize product and customer structures while enhancing cost control and operational quality[5]. - This earnings forecast is based on preliminary calculations and has not been audited by an external auditor[6]. - Investors are advised to exercise caution and consider investment risks due to the preliminary nature of the financial data[6].

Group 1 - The company Mingde Bio is planning to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. from Bluefan Medical Co., Ltd. through a cash transaction [1] - This transaction is expected to constitute a major asset restructuring but will not lead to a restructuring listing, involve share issuance, or constitute a related party transaction [1] - The company is currently advancing auditing, evaluation, and due diligence processes, and no formal agreement has been signed yet; the specific plan is still under discussion [1]

特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日披露了《关于筹划重大资产重组暨签署<股权收购意向协议>的提示性公告》 （公告编号：2025-056），已对本次交易涉及的相关事项进行了说明。 证券代码：002932 证券简称：明德生物 公告编号：2026-005 武汉明德生物科技股份有限公司 关于重大资产重组进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、风险提示 2、本次交易相关工作正在积极推进中，交易各方尚未签署正式协议。本次 交易尚存在较大不确定性，公司将根据相关事项的进展情况，分阶段及时履行信 息披露义务，敬请广大投资者关注公司后续公告，注意投资风险。 一、交易概述 公司拟以现金方式收购蓝帆医疗股份有限公司持有的武汉必凯尔救助用品 有限公司（以下简称"标的公司"）100%股权。本次交易完成后，标的公司将 成为公司的全资子公司。本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易拟采用现金方式，不构成重组上市，不涉及上市 公司发行股份。本次交易不构成关联交易，也不 ...

Core Viewpoint - Mingde Bio has signed an acquisition agreement to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for 35.71 million yuan, marking its entry into chronic disease management while continuing to focus on critical care diagnostics [1][5] Group 1: Acquisition Details - The acquisition involves a cash payment of 35.71 million yuan and will be executed through capital increase and equity acquisition [2] - After the transaction, Hunan Lanyi will become a subsidiary of Mingde Bio, with its shareholding structure adjusted accordingly [2] - Hunan Lanyi specializes in IVD instruments and reagents, particularly in glycated hemoglobin testing, which is positioned as a core product for chronic disease management [2] Group 2: Financial Performance and Projections - Hunan Lanyi is currently operating at a loss, with projected net losses of 20.68 million yuan for 2024 and 23.98 million yuan for the first three quarters of 2025 [3] - The acquisition includes a phased purchase mechanism and multiple performance guarantees, with conditions for future acquisitions based on Hunan Lanyi's financial performance from 2026 to 2028 [3][4] - If Hunan Lanyi meets specific performance criteria, Mingde Bio may acquire the remaining shares at a valuation not exceeding 504 million yuan [3] Group 3: Strategic Intent - This acquisition is part of Mingde Bio's strategy to expand its business amid pressure on its core operations, aiming to create a new growth curve through external expansion [5][6] - The company aims to integrate its critical care and chronic disease management capabilities, enhancing its service offerings across the healthcare continuum [6] - The acquisition is expected to open new market opportunities and customer bases, contributing to profit growth and breaking market barriers [6] Group 4: Financial Stability - The acquisition will be funded through the company's own resources, with payments structured to minimize cash flow impact [7] - The transaction is not expected to adversely affect the company's daily operations, financial stability, or liquidity [7]

Group 1 - The core viewpoint of the article highlights Mingde Biological's recent acquisition plans, including the purchase of a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd., following its acquisition of 100% of Wuhang Bikaier Rescue Supplies Co., Ltd. [1] - Hunan Lanyi is expected to remain in a loss position for 2024 and the first three quarters of 2025, indicating potential challenges for Mingde Biological's financial performance [1] - Mingde Biological has faced pressure on its performance, reporting a net profit loss for two consecutive years, which may be a driving factor behind its aggressive acquisition strategy [1]